# Virbac (Australia) Pty Limited

Chemwatch: 6095667

Issue Date: 12/10/2021 Version No: 6.1 Print Date: 08/30/2022 Safety Data Sheet according to WHS Regulations (Hazardous Chemicals) Amendment 2020 and ADG requirements L.GHS.AUS.EN.E

# SECTION 1 Identification of the substance / mixture and of the company / undertaking

#### **Product Identifier**

Product name	Cydectin Injection for Cattle	
Chemical Name	Not Applicable	
Synonyms	APVMA No.: 45663	
Chemical formula	Not Applicable	
Other means of identification	Not Available	

#### Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	Use according to manufacturer's directions.	

# Details of the supplier of the safety data sheet

Registered company name	Virbac (Australia) Pty Limited	
Address	361 Horsley Road Milperra NSW 2214 Australia	
Telephone	800 242 100	
Fax	+61 2 9772 9773	
Website	au.virbac.com	
Email	customercare@virbac.com.au	

#### Emergency telephone number

Association / Organisation	Poisons Information Centre	
Emergency telephone numbers	13 11 26	
Other emergency telephone numbers	Not Available	

#### **SECTION 2 Hazards identification**

#### Classification of the substance or mixture

# HAZARDOUS CHEMICAL. NON-DANGEROUS GOODS. According to the WHS Regulations and the ADG Code.

#### ChemWatch Hazard Ratings

	Min M	ax
Flammability	1	
Toxicity	1 📃	0 = Minimum
Body Contact	2	1 = Low
Reactivity	1 📕	2 = Moderate
Chronic	2	3 = High 4 = Extreme

Poisons Schedule	S6	
Classification <sup>[1]</sup>	Skin Corrosion/Irritation Category 2, Serious Eye Damage/Eye Irritation Category 2A, Specific Target Organ Toxicity - Repeated Exposure Category 2	
Legend: 1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex V		

Label elements



Hazard statement(s)

H315 Causes skin irritation. Chemwatch Hazard Alert Code: 2

H319	Causes serious eye irritation.	
H373	May cause damage to organs through prolonged or repeated exposure.	

#### Precautionary statement(s) Prevention

P260 Do not breathe mist/vapours/spray.		
P280	P280 Wear protective gloves, protective clothing, eye protection and face protection.	
P264	Wash all exposed external body areas thoroughly after handling.	

#### Precautionary statement(s) Response

P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.	
P314	Get medical advice/attention if you feel unwell.	
P337+P313	If eye irritation persists: Get medical advice/attention.	
P302+P352	IF ON SKIN: Wash with plenty of water.	
P332+P313	If skin irritation occurs: Get medical advice/attention.	
P362+P364	P362+P364 Take off contaminated clothing and wash it before reuse.	

# Precautionary statement(s) Storage

#### Not Applicable

#### Precautionary statement(s) Disposal

P501	Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.
------	--

Not Applicable

#### **SECTION 3 Composition / information on ingredients**

# Substances

See section below for composition of Mixtures

#### Mixtures

CAS No	%[weight]	Name
113507-06-5	1	moxidectin
Not Available	>60	Ingredients determined not to be hazardous
Legend:	1. Classified by Chernwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. Classification drawn from C&L * EU IOELVs available	

#### **SECTION 4 First aid measures**

Description of first aid measures			
Eye Contact	<ul> <li>If this product comes in contact with the eyes:</li> <li>Immediately hold eyelids apart and flush the eye continuously with running water.</li> <li>Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.</li> <li>Continue flushing until advised to stop by the Poisons Information Centre or a doctor, or for at least 15 minutes.</li> <li>Transport to hospital or doctor without delay.</li> <li>Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.</li> </ul>		
Skin Contact	<ul> <li>If skin contact occurs:</li> <li>Immediately remove all contaminated clothing, including footwear.</li> <li>Flush skin and hair with running water (and soap if available).</li> <li>Seek medical attention in event of irritation.</li> </ul>		
Inhalation	<ul> <li>If fumes, aerosols or combustion products are inhaled remove from contaminated area.</li> <li>Other measures are usually unnecessary.</li> </ul>		
Ingestion	<ul> <li>If swallowed do NOT induce vomiting.</li> <li>If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration.</li> <li>Observe the patient carefully.</li> <li>Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious.</li> <li>Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink.</li> <li>Seek medical advice.</li> </ul>		

#### Indication of any immediate medical attention and special treatment needed

For abamectin (avermectins):

Toxicity following accidental ingestion may be minimised by emesis-induction within one half hour of exposure. Since abamectin is thought to bind to glutamate-gated chloride ion channels, it is probably wise to avoid drugs that also interact with other ligand-gated chloride channels, including those that enhance GABA activity in patients with potentially toxic abamectin exposure

Avoid drugs that enhance GABA activity (barbiturate, benzodiazepines, valproic acid, etc.).

#### **SECTION 5 Firefighting measures**

#### Extinguishing media

- Water spray or fog.
- ▶ Foam.

- Dry chemical powder.
- BCF (where regulations permit).
- Carbon dioxide.

# Special hazards arising from the substrate or mixture

-	
Fire Incompatibility	Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result
lvice for firefighters	
Fire Fighting	<ul> <li>Alert Fire Brigade and tell them location and nature of hazard.</li> <li>Wear full body protective clothing with breathing apparatus.</li> <li>Prevent, by any means available, spillage from entering drains or water course.</li> <li>Use water delivered as a fine spray to control fire and cool adjacent area.</li> <li>Avoid spraying water onto liquid pools.</li> <li><b>DO NOT</b> approach containers suspected to be hot.</li> <li>Cool fire exposed containers with water spray from a protected location.</li> <li>If safe to do so, remove containers from path of fire.</li> </ul>
Fire/Explosion Hazard	<ul> <li>Combustible.</li> <li>Slight fire hazard when exposed to heat or flame.</li> <li>Heating may cause expansion or decomposition leading to violent rupture of containers.</li> <li>On combustion, may emit toxic fumes of carbon monoxide (CO).</li> <li>May emit acrid smoke.</li> <li>Mists containing combustible materials may be explosive.</li> <li>Combustion products include:</li> <li>carbon dioxide (CO2)</li> <li>other pyrolysis products typical of burning organic material.</li> <li>May emit corrosive fumes.</li> <li>May emit corrosive fumes.</li> </ul>
HAZCHEM	Not Applicable

# **SECTION 6** Accidental release measures

Personal precautions, protective equipment and emergency procedures

See section 8

#### **Environmental precautions**

See section 12

#### Methods and material for containment and cleaning up

Minor Spills	<ul> <li>Remove all ignition sources.</li> <li>Clean up all spills immediately.</li> <li>Avoid breathing vapours and contact with skin and eyes.</li> <li>Control personal contact with the substance, by using protective equipment.</li> <li>Contain and absorb spill with sand, earth, inert material or vermiculite.</li> <li>Wipe up.</li> <li>Place in a suitable, labelled container for waste disposal.</li> </ul>
Major Spills	<ul> <li>Moderate hazard.</li> <li>Clear area of personnel and move upwind.</li> <li>Alert Fire Brigade and tell them location and nature of hazard.</li> <li>Wear breathing apparatus plus protective gloves.</li> <li>Prevent, by any means available, spillage from entering drains or water course.</li> <li>No smoking, naked lights or ignition sources.</li> <li>Increase ventilation.</li> <li>Stop leak if safe to do so.</li> <li>Contain spill with sand, earth or vermiculite.</li> <li>Collect recoverable product into labelled containers for recycling.</li> <li>Absorb remaining product with sand, earth or vermiculite.</li> <li>Collect solid residues and seal in labelled drums for disposal.</li> <li>Wash area and prevent runoff into drains.</li> <li>If contamination of drains or waterways occurs, advise emergency services.</li> </ul>

Personal Protective Equipment advice is contained in Section 8 of the SDS.

# **SECTION 7 Handling and storage**

Precautions for safe handling				
Safe handling	<ul> <li>Avoid all personal contact, including inhalation.</li> <li>Wear protective clothing when risk of exposure occurs.</li> <li>Use in a well-ventilated area.</li> <li>Prevent concentration in hollows and sumps.</li> <li>DO NOT enter confined spaces until atmosphere has been checked.</li> <li>Avoid smoking, naked lights or ignition sources.</li> <li>Avoid contact with incompatible materials.</li> <li>When handling, DO NOT eat, drink or smoke.</li> <li>Keep containers securely sealed when not in use.</li> <li>Avoid physical damage to containers.</li> <li>Always wash hands with soap and water after handling.</li> <li>Work clothes should be laundered separately.</li> <li>Use good occupational work practice.</li> <li>Observe manufacturer's storage and handling recommendations contained within this SDS.</li> <li>Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions.</li> </ul>			

	DO NOT allow clothing wet with material to stay in contact with skin
Other information	<ul> <li>Store in original containers.</li> <li>Keep containers securely sealed.</li> <li>No smoking, naked lights or ignition sources.</li> <li>Store in a cool, dry, well-ventilated area.</li> <li>Store away from incompatible materials and foodstuff containers.</li> <li>Protect containers against physical damage and check regularly for leaks.</li> <li>Observe manufacturer's storage and handling recommendations contained within this SDS.</li> </ul>

#### Conditions for safe storage, including any incompatibilities

Suitable container	<ul> <li>Metal can or drum</li> <li>Packaging as recommended by manufacturer.</li> <li>Check all containers are clearly labelled and free from leaks.</li> </ul>
Storage incompatibility	Avoid reaction with oxidising agents

# **SECTION 8 Exposure controls / personal protection**

# **Control parameters**

#### Occupational Exposure Limits (OEL)

INGREDIENT DATA

#### Not Available

Emergency Limits

Ingredient	TEEL-1	TEEL-2		TEEL-3
Cydectin Injection for Cattle	Not Available	Not Available		Not Available
Ingredient	Original IDLH		Revised IDLH	
moxidectin	Not Available		Not Available	
Occupational Exposure Banding			0	<b>D</b>
Ingredient	Occupational Exposure Band Rating		Occupational Expos	ure Band Limit
moxidectin	E		≤ 0.01 mg/m³	
Notes:	Occupational exposure banding is a process of assigning chemicals into specific categories or bands based on a chemical's potency and the adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to a range of exposure concentrations that are expected to protect worker health.			

#### MATERIAL DATA

# Exposure controls

	Engineering controls are used to remove a hazard or place a be highly effective in protecting workers and will typically be in The basic types of engineering controls are: Process controls which involve changing the way a job activit Enclosure and/or isolation of emission source which keeps a "adds" and "removes" air in the work environment. Ventilation ventilation system must match the particular process and che Employers may need to use multiple types of controls to prev General exhaust is adequate under normal operating condition overexposure exists, wear approved respirator. Correct fit is or closed storage areas. Air contaminants generated in the w velocities" of fresh circulating air required to effectively removing the output of the storage areas.	ndependent of worker interactions to provide this high level ty or process is done to reduce the risk. selected hazard "physically" away from the worker and ven o can remove or dilute an air contaminant if designed proper emical or contaminant in use. vent employee overexposure. Dons. Local exhaust ventilation may be required in specific cin essential to obtain adequate protection. Provide adequate v rorkplace possess varying "escape" velocities which, in turn	of protection. tilation that strategically iy. The design of a coumstances. If risk of entilation in warehouse
	Type of Contaminant:		Air Speed:
	solvent, vapours, degreasing etc., evaporating from tank (in still air).		0.25-0.5 m/s (50-100 f/min)
Appropriate engineering	aerosols, fumes from pouring operations, intermittent conta drift, plating acid fumes, pickling (released at low velocity in	0.5-1 m/s (100-200 f/min.)	
controls	direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)		1-2.5 m/s (200-500 f/min.)
	grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion).		2.5-10 m/s (500-2000 f/min.)
	Within each range the appropriate value depends on:		
	Lower end of the range	Upper end of the range	
	1: Room air currents minimal or favourable to capture	1: Disturbing room air currents	
	2: Contaminants of low toxicity or of nuisance value only.	2: Contaminants of high toxicity	
	3: Intermittent, low production.	3: High production, heavy use	
	4: Large hood or large air mass in motion	4: Small hood-local control only	
	Simple theory shows that air velocity falls rapidly with distance with the square of distance from the extraction point (in simpl accordingly, after reference to distance from the contaminatin 1-2 m/s (200-400 f/min) for extraction of solvents generated is producing performance deficits within the extraction apparatu- more when extraction systems are installed or used.	le cases). Therefore the air speed at the extraction point sho ng source. The air velocity at the extraction fan, for example n a tank 2 meters distant from the extraction point. Other mo	buld be adjusted, , should be a minimum of echanical considerations,

Page **5** of **10** 

# Cydectin Injection for Cattle

Personal protection	
Eye and face protection	<ul> <li>Safety glasses with side shields.</li> <li>Chemical goggles.</li> <li>Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent]</li> </ul>
Skin protection	See Hand protection below
Hands/feet protection	<ul> <li>Wear chemical protective gloves, e.g. PVC.</li> <li>Wear safely footwear or safety gumboots, e.g. Rubber</li> <li>The selection of suitable gloves does not only depend on the material, but also on further marks of quality which vary from manufacturer to manufacturer. Where the chemical is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application.</li> <li>The selection gloves does not only depend on the manufacturer of the protective gloves and has to be observed when making a final choice.</li> <li>Personal hygiene is a key element of effective hand care. Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.</li> <li>Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include:         <ul> <li>frequency and duration of contact.</li> <li>chemical resistance of glove material,</li> <li>glove thickness and</li> <li>detritity</li> </ul> </li> <li>Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739, AS/NZS 2161.1 or national equivalent).</li> <li>When only brief contact is expected, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374, AS/NZS 2161.1.0 or national equivalent).</li> <li>Some gloves polymer types are less affected by movement and this should be taken into account when considering gloves for long-term use.</li> <li>Contaminated gloves should be replaced.</li> <li>Scelent when breakthrough time &gt; 480 min</li> <li>Good when breakthrough time &gt; 20 min</li> <li>Fair when breakthrough time &gt; 20 min</li> <li>Fair when breakthrough time &gt; 20 min</li> <li>For general applications, gloves with a kinkness typically g</li></ul>
Body protection	See Other protection below
Body protection	Overalls.
Other protection	<ul> <li>P.V.C apron.</li> <li>Barrier cream.</li> <li>Skin cleansing cream.</li> <li>Eye wash unit.</li> </ul>

# Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:

"Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the *computer-generated* selection:

```
Cydectin Injection for Cattle
```

Material	СРІ
BUTYL	С
NATURAL RUBBER	С
NEOPRENE	С
PE/EVAL/PE	С
PVA	С
VITON	С

# **Respiratory protection**

Type A-P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Selection of the Class and Type of respirator will depend upon the level of breathing zone contaminant and the chemical nature of the contaminant. Protection Factors (defined as the ratio of contaminant outside and inside the mask) may also be important.

Required minimum protection factor	Maximum gas/vapour concentration present in air p.p.m. (by volume)	Half-face Respirator	Full-Face Respirator
up to 10	1000	A-AUS / Class1 P2	-
up to 50	1000	-	A-AUS / Class 1 P2
up to 50	5000	Airline *	-
up to 100	5000	-	A-2 P2
up to 100	10000	-	A-3 P2
100+			Airline**

\* CPI - Chemwatch Performance Index

A: Best Selection

B: Satisfactory; may degrade after 4 hours continuous immersion

C: Poor to Dangerous Choice for other than short term immersion

\* - Continuous Flow \*\* - Continuous-flow or positive pressure demand

NOTE: As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -

\* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted. A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

- Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content.
- The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too high, or that the mask is not properly fitted. Because of these limitations, only restricted use of cartridge respirators is considered appropriate.
- Cartridge performance is affected by humidity. Cartridges should be changed after 2 hr of continuous use unless it is determined that the humidity is less than 75%, in which case, cartridges can be used for 4 hr. Used cartridges should be discarded daily, regardless of the length of time used

#### **SECTION 9** Physical and chemical properties

Information on basic physical and chemical properties

Appearance	Liquid (injectable solution).		
Physical state	Liquid	Relative density (Water = 1)	1.040
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Available
pH (as supplied)	Not Applicable	Decomposition temperature (°C)	Not Available
Melting point / freezing point (°C)	Not Available	Viscosity (cSt)	Not Available
Initial boiling point and boiling range (°C)	Not Available	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	Not Available	Taste	Not Available
Evaporation rate	Not Available	Explosive properties	Not Available
Flammability	Not Available	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Available	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	Not Available	Volatile Component (%vol)	Not Available
Vapour pressure (kPa)	Not Available	Gas group	Not Available
Solubility in water	Miscible	pH as a solution (Not Available%)	Not Available
Vapour density (Air = 1)	Not Available	VOC g/L	Not Available

#### **SECTION 10 Stability and reactivity**

Reactivity	See section 7
Chemical stability	<ul> <li>Unstable in the presence of incompatible materials.</li> <li>Product is considered stable.</li> <li>Hazardous polymerisation will not occur.</li> </ul>
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

#### **SECTION 11 Toxicological information**

#### Information on toxicological effects

Inhaled	The material is not thought to produce either adverse health effects or irritation of the respiratory tract following inhalation (as classified by EC Directives using animal models). Nevertheless, adverse systemic effects have been produced following exposure of animals by at least one other route and good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting.
Ingestion	Accidental ingestion of the material may be damaging to the health of the individual.
Skin Contact	Limited evidence exists, or practical experience predicts, that the material either produces inflammation of the skin in a substantial number of individuals following direct contact, and/or produces significant inflammation when applied to the healthy intact skin of animals, for up to four hours, such inflammation being present twenty-four hours or more after the end of the exposure period. Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidermis. Open cuts, abraded or irritated skin should not be exposed to this material Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects.

	Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.		
Eye	Limited evidence exists, or practical experience suggests, that the material may cause eye irritation in a substantial number of individuals and/or is expected to produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals. Repeated or prolonged eye contact may cause inflammation characterised by temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur.		
Chronic	Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems. Serious damage (clear functional disturbance or morphological change which may have toxicological significance) is likely to be caused by repeated or prolonged exposure. As a rule the material produces, or contains a substance which produces severe lesions. Such damage may become apparent following direct application in subchronic (90 day) toxicity studies or following sub-acute (28 day) or chronic (two-year) toxicity tests. Harmful: danger of serious damage to health by prolonged exposure if swallowed.		
	тохісітү	IRRITATION	
Cydectin Injection for Cattle	Not Available	Not Available	
	тохісіту	IRRITATION	
moxidectin	Dermal (rabbit) LD50: >2000 mg/kg <sup>[2]</sup>	Eye (rabbit): slight irritant *	
	Oral (Mouse) LD50; 42 mg/kg <sup>[2]</sup>	Skin (rabbit): non-irritant *	
Legend:	1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2.* Value obtained from manufacturer's SDS. Unless otherwise		

d: 1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2.\* Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances

May produce developmental toxicity in rat offspring at maternally toxic doses. This does not occur in rabbits. \*\* Cyanamid The ADI for Moxidectin is set at 0.01mg/kg/day. The corresponding NOEL is set at 1mg/kg/day. ADI means Acceptable Daily Intake and NOEL means No-observableeffect-level. In rats given oral doses of moxidectin, decreased activity, prostration, tremors, chromodacryorrhea, decreased respiration, diarrhoea, hypersensitivity to touch and sound, and epistaxis occurred. Congestion of the liver, kidneys and lungs were observed in animals that died, but animals which were sacrificed at the end of the 14-day observation period showed no abnormalities. No overt signs of toxicity were noted in rabbits treated dermally with moxidectin. Studies of moxidectin show the side effects vary by animal and may be affected by the product's formulation, application method and dosage. An overdose of moxidectin enhances the effect of gamma-aminobutyric acid (GABA) in the central nervous system. In horses, overdose may lead to depression, drooping of the lower lip, tremor, lack of coordination when moving (taxia), decreased rate of breathing (respiratory rate), stupor and coma. If a dog licks moxidectin from the skin which was applied as a "spot-on" (topical) treatment, this has the same effect as an overdose, and may cause vomiting, salivation and neurological signs such as ataxia, tremor, and nystagmus Collie dogs cannot be administered moxidectin

For avermectins:

MOXIDECTIN

Technical avermectin exhibits high mammalian acute toxicity. In vertebrates, the effects occur via poisoning of the central nervous system (CNS) through reactions at the receptor for the inhibitory neurotransmitter GABA. The avermectins open the GABAA receptor chloride channel by binding to the GABA receptor site (receptor protein) and act as partial agonists.. Chloride ions then flow into the postsynaptic neuron. This chloride permeability increase can significantly hyperpolarize (make more negative) the membrane potential, which has a dampening effect on nerve impulse firing. There is also a reversible dose-dependent increase in chloride ion permeability in response to very low doses of avermectins.

In GABA-insensitive neurons with no inhibitory innervation, the avermectins induce an irreversible increase in chloride ion conductance through interacting with voltage-dependent chloride channels. Avermectin intoxication in mammals begins with hyperexcitability, tremors, and incoordination and later develops into ataxia and coma-like sedation. This is similar to the mode of action of ethanol and barbiturates and benzodiazepine sedatives However, the avermectins are less specific in their action and can affect a variety of other ligand- and voltage-gated chloride channels. The general safety of the avermectins depends on the presence of an intact P-glycoprotein blood-brain barrier Avermectin is not considered to be mutagenic and does not sensitise skin. It is not readily absorbed by mammals and the majority of the residue is excreted in the faeces within 2 days. The 24-month rat chronic feeding/ oncogenicity study and 94-week mouse chronic toxicity oncogenicity study were negative for oncogenic potential. The results of a series of developmental toxicity studies (rat, rabbit, mouse) have been evaluated and showed that avermectin B1 produces developmental toxicity (cleft palate) in the CF1 mouse. Toxicology data were also evaluated for the delta-8,9-isomer of avermectin B1 which is a plant photodegradate that can range between 5 and 20 percent of the residue on/in cottonseed. This isomer possesses avermectin-like toxicological activity. It was concluded that the delta 8,9-isomer also produces developmental toxicity (cleft palate) in mice, but not in rats. In addition to avermectin and its delta 8,9-isomer, toxicology data were also evaluated for the "polar degradates" of avermectin, which constitute a large percentage (up to 70%) of the total residue on cottonseed. Review of the toxicology data indicated that these polar degradates do not possess avermectin-like toxicological activity and for this reason need not be included in the

tolerance expression for residues in/on cottonseed. Abamectin (a mixture of avermectin isomers) is a reproductive toxin in laboratory animals at doses which are acutely toxic to the mother. In development toxicity studies with abamectin, cleft palates were seen in mice and rabbits and clubbing of the forepaws was seen in rabbits. The no-observed-adverse-effect-level (NOAEL) for maternal and developmental toxicity in rabbits was 1 mg/kg/day. In CF-1 mice, a strain recognised to be particularly sensitive to avermectins, the NOAEL for maternal toxicity was 0.05 mg/kg/day and the NOAEL for malformations was 0.2 mg/kg/day. Studies show that the sensitivity of a subpopulation of CF-1 mice to avermectins is due to the absence of a transmembrane P-glycoprotein, a significant component of the blood-brain interface that normally acts as a non-selective protective barrier in a wide range of species including humans. CF-1 mice are therefore an unlikely candidate for assessing human risk. No evidence of developmental toxicity was seen in oral studies in rats in the absence of maternal toxicity (NOAEL = 1.6 mg/kg/day). In a rat multigenerational reproduction study, pup toxicity and deaths were seen at 0.4 mg/kg/day (NOAEL = 0.12 mg/kg/day). Neonatal rats are not an appropriate model for assessing human risk in humans because (a) rat milk has a greater fat content than human breast milk and abamectin concentrates in fat; (b) on a weight basis, the neonatal rat consumes significantly greater quantities of milk than the newborn human and (c) the blood brain barrier in rodents is formed post-natally (as evidenced by low P-glycoprotein levels) while in humans this membrane is formed pre-natally.

Ivermectin, a close structural analogue, has been used extensively in the treatment of human onchocerciasis at an oral therapeutic dose of 0.2 mg/kg, without serious drug-related effects. Despite its wide usage in animals and humans, ivermectin does dot appear to produce birth defects. Abamectin is non-mutagenic in the Ames test and the micronucleus test.

Dietary carcinogenicity studies in mice and rats showed negative results. In a 14-week oral study in monkeys no effects were seen at 0.2, 0.5 or 1.0 mg/kg/day; emesis was seen at 2.0 mg/kg/day; delayed pupillary obstruction at 6 and 8 mg/kg/day and mydriasis at 12 mg/kg/day. In chronic oral toxicity, abamectin produced decreased body weight gain in mice (no-observed-adverse-effect-level (NOAEL) = 1.5 mg/kg/day); tremors in rats (NOAEL = 1.5 mg/kg/day), weight loss, tremors, mydriasis, liver and gall bladder changes and death in dogs (NOAEL = 0.25 mg/kg/day); and emesis, mydriasis and sedation in monkeys (NOAL = 1 mg/kg/day).

Acute Toxicity	×	Carcinogenicity	×
Skin Irritation/Corrosion	×	Reproductivity	×
Serious Eye Damage/Irritation	×	STOT - Single Exposure	×

# Respiratory or Skin sensitisation X STOT - Repeated Exposure X Mutagenicity X Aspiration Hazard X Legend: X - Data either not available or does not fill the criteria for classification

Data available to make classification

#### **SECTION 12 Ecological information**

#### Toxicity

Cydectin Injection for Cattle	Endpoint	Test Duration (hr)	Species	Value	Source
	Not Available	Not Available	Not Available	Not Available	Not Available
	Endpoint	Test Duration (hr)	Species	Value	Source
moxidectin	EC50	72h	Algae or other aquatic plants	>0.087mg/L	Not Available
	EC50	48h	Crustacea	<0.001mg/L	Not Availabl
	NOEC(ECx)	96h	Fish	<0.001mg/L	Not Availabl
	LC50	96h	Fish	0.001mg/L	Not Available
Legend:	Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan - Bioconcentration Data 8. Vendor Data				

# DO NOT discharge into sewer or waterways.

#### Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air	
	No Data available for all ingredients	No Data available for all ingredients	
Bioaccumulative potential			
Ingredient	Bioaccumulation		
	No Data available for all ingredients		
Mobility in soil			
Ingredient	Mobility		
	No Data available for all ingredients		

# **SECTION 13 Disposal considerations**

Waste treatment methods	
Product / Packaging disposal	<ul> <li>DO NOT allow wash water from cleaning or process equipment to enter drains.</li> <li>It may be necessary to collect all wash water for treatment before disposal.</li> <li>In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first.</li> <li>Where in doubt contact the responsible authority.</li> <li>Recycle wherever possible or consult manufacturer for recycling options.</li> <li>Consult State Land Waste Authority for disposal.</li> <li>Bury or incinerate residue at an approved site.</li> <li>Recycle containers if possible, or dispose of in an authorised landfill.</li> <li>Containers may still present a chemical hazard/ danger when empty.</li> <li>Return to supplier for reuse/ recycling if possible.</li> <li>Otherwise:</li> <li>If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill.</li> <li>Where possible retain label warnings and SDS and observe all notices pertaining to the product.</li> </ul>

# **SECTION 14 Transport information**

# Labels Required

Marine Pollutant	NO	
HAZCHEM	Not Applicable	

Land transport (ADG): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Transport in bulk according to Annex II of MARPOL and the IBC code

# Not Applicable

Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group
moxidectin	Not Available
Transport in bulk in accordan	ce with the ICG Code
Product name	Ship Type
moxidectin	Not Available

#### **SECTION 15 Regulatory information**

#### Safety, health and environmental regulations / legislation specific for the substance or mixture

#### moxidectin is found on the following regulatory lists

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) -Schedule 4 Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) -Schedule 6 Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) -Schedule 7

#### **National Inventory Status**

Schedule 5

National Inventory	Status		
Australia - AIIC / Australia Non-Industrial Use	No (moxidectin)		
Canada - DSL	No (moxidectin)		
Canada - NDSL	No (moxidectin)		
China - IECSC	No (moxidectin)		
Europe - EINEC / ELINCS / NLP	No (moxidectin)		
Japan - ENCS	No (moxidectin)		
Korea - KECI	o (moxidectin)		
New Zealand - NZIoC	/es		
Philippines - PICCS	lo (moxidectin)		
USA - TSCA	No (moxidectin)		
Taiwan - TCSI	Yes		
Mexico - INSQ	No (moxidectin)		
Vietnam - NCI	No (moxidectin)		
Russia - FBEPH	No (moxidectin)		
Legend:	Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.		

#### **SECTION 16 Other information**

Revision Date	12/10/2021
Initial Date	05/13/2016

#### SDS Version Summary

Version	Date of Update	Sections Updated	
5.1	11/01/2019	One-off system update. NOTE: This may or may not change the GHS classification	
6.1	12/10/2021	Classification change due to full database hazard calculation/update.	

#### Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

#### Definitions and abbreviations

PC – TWA: Permissible Concentration-Time Weighted Average PC – STEL: Permissible Concentration-Short Term Exposure Limit IARC: International Agency for Research on Cancer ACGIH: American Conference of Governmental Industrial Hygienists STEL: Short Term Exposure Limit TEEL: Temporary Emergency Exposure Limit, IDLH: Immediately Dangerous to Life or Health Concentrations ES: Exposure Standard OSF: Odour Safety Factor NOAEL :No Observed Adverse Effect Level LOAEL: Lowest Observed Adverse Effect Level

TLV: Threshold Limit Value

LOD: Limit Of Detection

OTV: Odour Threshold Value BCF: BioConcentration Factors BEI: Biological Exposure Index AIIC: Australian Inventory of Industrial Chemicals DSL: Domestic Substances List NDSL: Non-Domestic Substances List IECSC: Inventory of Existing Chemical Substance in China EINECS: European INventory of Existing Commercial chemical Substances ELINCS: European List of Notified Chemical Substances NLP: No-Longer Polymers ENCS: Existing and New Chemical Substances Inventory KECI: Korea Existing Chemicals Inventory NZIoC: New Zealand Inventory of Chemicals PICCS: Philippine Inventory of Chemicals and Chemical Substances TSCA: Toxic Substances Control Act TCSI: Taiwan Chemical Substance Inventory INSQ: Inventario Nacional de Sustancias Químicas NCI: National Chemical Inventory FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances

This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH. TEL (+61 3) 9572 4700.

